RxDoctor Payments Data

Amy Torres

Family · Cleveland, OHNPI 1992151260

Payments from drug & device makers

$2,834in general payments, 2019–2025

Across 75 payments — averaging $37.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Medtronic$985
  • BETA Bionics, Inc.$225
  • Astellas Pharma US Inc$195
  • Incyte Corporation$193
  • Jazz Pharmaceuticals Inc.$108
  • plus $92 from 4 others

What the payments were for

  • Travel & lodging$93333%
  • Food & beverage$1,60657%
  • Education$29410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,834 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$18,886
Medicare patients
155
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$125,374
MounjaroTirzepatide78$83,879
TrulicityDulaglutide40$54,277
JardianceEmpagliflozin30$28,966
JanuviaSitagliptin Phosphate20$20,918
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$7,475
Tresiba Flextouch U-100Insulin Degludec11$6,013
Humalog Kwikpen U-100Insulin Lispro23$4,680
Nano 2nd Gen Pen NeedlePen Needle, Diabetic31$2,792
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic30$2,367
SynthroidLevothyroxine Sodium24$2,340
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic11$1,512
LantusInsulin Glargine,hum.Rec.Anlog14$1,378
Novolog FlexpenInsulin Aspart12$1,334
Levothyroxine Sodium101$1,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$39$125,374109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →